Comparing two blood treatments for Guillain-Barré syndrome
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial compares two blood-based treatments for Guillain-Barré syndrome: one that filters antibodies from the blood (immunoadsorption) and one that uses donated antibodies (IVIG). Both aim to reduce nerve damage and speed up recovery, and researchers want to see which works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of Guillain-Barré syndrome.
- Your symptoms must have started within the last 2 weeks.
- You must be between 18 and 60 years old.
- You should be unable to walk on your own (or need help) due to the condition.
- You must not be pregnant or have other autoimmune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether an experimental drug called efgartigimod (given as an infusion) can help people with Guillain-Barré syndrome recover faster. It is for adults who recently developed symptoms and have significant weakness that affects their walking.
This trial studies whether an inpatient rehabilitation program can help people with Guillain-Barré syndrome. It may be useful if you need structured therapy and support during recovery.
This trial tests whether noninvasive breathing support (like a mask or nasal prongs) can help people with Guillain-Barré syndrome who have trouble breathing. It aims to see if this approach can avoid the need for a breathing tube.
This trial tests a new medicine, tanruprubart (also called ANX005), for people with Guillain-Barré syndrome. It aims to see if the drug can help improve recovery when given soon after symptoms start.
This study tests if ultrasound can find nerve problems in people with Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP), and if it helps doctors diagnose and predict outcomes early.
This study looks at how Guillain-Barré syndrome, a condition that causes muscle weakness, might affect the heart in children. It aims to find out if there are heart problems that need extra care.
Hear when a new Guillain Barré Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.